10 results · 16ms · Sources: EU EUDAMED, US FDA

Get notified when this changes

We'll email you when new records match this search — new devices, new clearances, certificate changes, or withdrawals.

Cepheid Xpert MRSA/MRSA NxG Control Panel (Catalog #8195) UDI: 70845357041226 Product Usage: On April 9, 2019, Microbiologics sent ACTION REQUIRED: MEDICAL DEVICE CORRECTION emails to their direct US consignees requesting them to complete a MEDICAL DEVICE CORRECTION FORM indicating how much product they had on hand.

FDA Enforcement
Class II ·Ongoing·Microbiologics Inc·June 12, 2019

Cepheid Xpert SA Nasal Complete Control Panel (Catalog #8196) UDI: 70845357041233 Product Usage: On April 9, 2019, Microbiologics sent ACTION REQUIRED: MEDICAL DEVICE CORRECTION emails to their direct US consignees requesting them to complete a MEDICAL DEVICE CORRECTION FORM indicating how much product they had on hand.

FDA Enforcement
Class II ·Ongoing·Microbiologics Inc·June 12, 2019

Cepheid, Sample Collection Device, Part: 900-0370

FDA Enforcement
Class II ·Ongoing·Cepheid·August 21, 2024

Cepheid Xpert C. difficile/Epi Control Panel

FDA Enforcement
Class III ·Ongoing·Microbiologics Inc·June 26, 2019

Brand Name: Xpert¿ BCR-ABL Ultra Model/Catalog Number: GXBCRABL-US-10

FDA Enforcement
Class II ·Ongoing·Cepheid·December 24, 2025

Brand Name: Xpert¿ BCR-ABL Ultra Model/Catalog Number: GXBCRABL-10

FDA Enforcement
Class II ·Ongoing·Cepheid·December 24, 2025

Xpert MTB/RIF. Model Number: GXMTB/RIF-US-10.

FDA Enforcement
Class II ·Ongoing·Cepheid·December 3, 2025

Xpert Xpress Strep A, XPRSTREPA-10, P/N: 302-2294 IVD, Rx Only

FDA Enforcement
Class II ·Ongoing·Cepheid·November 8, 2023

Xpert Xpress Strep A, REF:Xprstrepa-CE-10, CE IVD,

FDA Enforcement
Class II ·Ongoing·Cepheid·November 8, 2023

Xpert SA Nasal Complete Catalog Number: GXSACOMP-10 UDI-DI code: 07332940000158 Xpert SA Nasal Complete kit; 10 test kit: A collection of reagents and other associated materials intended to be used for the direct qualitative and/or quantitative detection of nucleic acid from methicillin-resistant and methicillin-susceptible Staphylococcus aureus (MRSA/MSSA) bacteria present in a clinical specimen, using a nucleic acid technique

FDA Enforcement
Class II ·Ongoing·Cepheid·November 5, 2025